133 related articles for article (PubMed ID: 1647501)
21. A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma--a multi-centre clinical study.
Kaisary AV; Ryan PG; Turkes A; Peeling WB; Griffiths K
Prog Clin Biol Res; 1988; 260():89-100. PubMed ID: 2966408
[No Abstract] [Full Text] [Related]
22. Effects of gonadotropin-releasing hormone and its agonists on prolactin secretion from normal and tumorous pituitary cells.
Lamberts SW; Uitterlinden P; Reubi JC; de Jong FH
Neuroendocrinology; 1989 Feb; 49(2):157-63. PubMed ID: 2524674
[TBL] [Abstract][Full Text] [Related]
23. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis.
Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR
Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047
[TBL] [Abstract][Full Text] [Related]
24. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
Murphy GP; Greco J; Huben R
Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064
[TBL] [Abstract][Full Text] [Related]
25. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
[TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
27. Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate?
Samdal F; Vada K; Lundmo PI; Mjølnerød OK
Scand J Urol Nephrol; 1991; 25(3):197-9. PubMed ID: 1835129
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
Limonta P; Dondi D; Moretti RM; Maggi R; Motta M
J Clin Endocrinol Metab; 1992 Jul; 75(1):207-12. PubMed ID: 1320049
[TBL] [Abstract][Full Text] [Related]
29. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
[TBL] [Abstract][Full Text] [Related]
30. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Lunglmayr G
Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
[No Abstract] [Full Text] [Related]
31. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
32. Zoladex treatment of symptomatic prostatic carcinoma.
Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
[TBL] [Abstract][Full Text] [Related]
33. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
Kaisary AV; Tyrrell CJ; Peeling WB; Griffiths K
Br J Urol; 1991 May; 67(5):502-8. PubMed ID: 1828183
[TBL] [Abstract][Full Text] [Related]
34. Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer.
Kuber W; Viehberger G; Zeillinger R; Spona J
Urol Res; 1991; 19(1):19-24. PubMed ID: 1827557
[TBL] [Abstract][Full Text] [Related]
35. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
Peeling WB
Prog Clin Biol Res; 1989; 303():41-5. PubMed ID: 2528738
[No Abstract] [Full Text] [Related]
36. Re: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. A. V. Kaisary et al. Br. J. Urol., 67, 502-508, 1991.
Bunce C
Br J Urol; 1992 Apr; 69(4):441-2. PubMed ID: 1533812
[No Abstract] [Full Text] [Related]
37. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
Fernandez del Moral P; Litjens TT; Weil EH; Debruyne FM
Urology; 1988 Aug; 32(2):137-40. PubMed ID: 2969641
[TBL] [Abstract][Full Text] [Related]
38. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
[TBL] [Abstract][Full Text] [Related]
39. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
[TBL] [Abstract][Full Text] [Related]
40. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
